<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anemia of prematurity (AOP)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anemia of prematurity (AOP)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anemia of prematurity (AOP)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Erythropoiesis decreases markedly after birth. This occurs due to the onset of breathing and closure of the ductus arteriosus, which increase tissue oxygenation and reduce production of erythropoietin (EPO) [<a href="#rid1">1</a>]. In healthy term infants, a mild anemia develops as hemoglobin (Hgb) levels decline over the first 8 to 12 weeks after birth (referred to as the "physiologic nadir") (<a class="graphic graphic_figure graphicRef81464" href="/d/graphic/81464.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia", section on 'Age of patient'</a>.)</p><p>Preterm infants have lower Hgb values at birth compared with term infants and the postnatal decline in Hgb occurs earlier and is more pronounced than the physiologic anemia seen in term infants. This is compounded by other factors that contribute to more severe anemia (blood loss from phlebotomy, reduced red blood cell [RBC] lifespan, depleted iron stores). Together, these processes are referred to as anemia of prematurity (AOP).</p><p>The pathogenesis, clinical features, and management of AOP will be reviewed here, including a summary of indications for RBC transfusion in preterm neonates. A more detailed discussion of RBC transfusion in neonates is proved separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p class="headingAnchor" id="H4145599177"><span class="h1">DEFINITIONS OF PREMATURITY</span><span class="headingEndMark"> — </span>Definitions of different degrees of prematurity based upon gestational age (GA; which is calculated from the first day of the mother's last period) or birth weight (BW) are provided in the table (<a class="graphic graphic_table graphicRef119362" href="/d/graphic/119362.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2"><span class="h1">CAUSES AND CONTRIBUTING FACTORS</span><span class="headingEndMark"> — </span>The primary cause of AOP is the impaired ability to increase serum erythropoietin (EPO) appropriately in the setting of anemia and decreased tissue availability of oxygen [<a href="#rid2">2,3</a>]. Circulating and bone marrow red cell progenitors respond to EPO, if present, indicating that the impaired erythropoiesis is due to lack of EPO, not a failure to respond to the hormone [<a href="#rid4">4-6</a>]. Other hematopoietic growth factors (eg, granulocyte-macrophage colony-stimulating factor) are not affected.</p><p>While AOP is directly due to impaired EPO production, several other factors can contribute to anemia in preterm infants, including blood loss from phlebotomy, reduced red blood cell life span, and iron depletion.</p><p class="headingAnchor" id="H3"><span class="h2">Impaired erythropoietin production</span><span class="headingEndMark"> — </span>EPO is produced by the fetal liver and the cortical interstitial cells of the kidney in response to hypoxia. Its production is regulated by the transcription factor hypoxia inducible factor-1 (HIF-1). Its primary function is to regulate erythrocyte production. EPO does not cross the placenta; fetal production increases with gestational age [<a href="#rid7">7-10</a>].</p><p>In preterm infants, EPO levels increase modestly in response to anemia and tissue hypoxia; however, the response is less than what is seen in older children and adults with the same degree of anemia [<a href="#rid2">2,11</a>]. (See  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p>In AOP, the specific mechanisms leading to the discrepancy between serum EPO concentration and the severity of the anemia are uncertain. Proposed pathogenetic pathways involve the site of EPO production and the developmental regulation of transcription factors in the liver versus the kidney.</p><p class="bulletIndent1"><span class="glyph">●</span>The liver is the principal site of EPO production in the fetus [<a href="#rid12">12,13</a>]. The feedback increase in hepatic EPO mRNA in response to anemia or hypoxia may be less than that of the kidney [<a href="#rid14">14</a>]. EPO mRNA expression in the kidney is present in the fetus, and increases significantly after 30 weeks gestation, suggesting that the switch to the kidney as the main site of EPO production is developmentally regulated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fetal or neonatal environment may alter the response to hypoxic signals by the liver. Support for this hypothesis comes from the observation that hepatic transplantation from fetal and neonatal lambs into adult sheep increased EPO production by the transplanted liver [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transcriptional regulatory factors, such as HIF-1, may contribute to low levels of EPO in preterm infants. These factors activate target genes, including those encoding EPO, in response to decreased cellular oxygen concentration [<a href="#rid16">16,17</a>]. They appear to be developmentally regulated in some fetal tissues, which might account for the decreased expression of EPO in response to anemia in preterm infants [<a href="#rid1">1,18</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Blood loss from phlebotomy</span><span class="headingEndMark"> — </span>Iatrogenic blood loss due to phlebotomy for blood tests is a major contributor to anemia in preterm neonates. There is a strong correlation between the amount of blood lost from phlebotomy and the number of transfusions preterm neonates require [<a href="#rid19">19</a>]. The volume of blood loss increases with illness severity and decreasing gestational age since critically ill, extremely preterm neonates tend to require more frequent laboratory tests [<a href="#rid20">20,21</a>]. Phlebotomy-related blood loss in preterm infants may be greater than is necessary for the care of the neonate [<a href="#rid22">22</a>]. </p><p>Strategies to reduce iatrogenic blood loss include: </p><p class="bulletIndent1"><span class="glyph">●</span>Limiting blood sampling to essential testing only </p><p class="bulletIndent1"><span class="glyph">●</span>Using microtechniques (sampling and testing with very small volumes of blood)</p><p class="bulletIndent1"><span class="glyph">●</span>Using point-of care devices that can perform testing on small blood volumes</p><p class="bulletIndent1"><span class="glyph">●</span>Using noninvasive methods for monitoring when possible (eg, pulse oximetry and transcutaneous carbon dioxide monitors [TCOM] rather than frequent blood gas sampling) </p><p></p><p>In studies involving extremely low birth weight (ELBW; &lt;1000 g) infants, total phlebotomy-related blood loss reached approximately 40 to 50 mL/kg by the end of the second week of the neonatal intensive care unit (NICU) stay and 80 mL/kg after 10 weeks [<a href="#rid19">19,21</a>]. In one study, approximately 50 percent of iatrogenic blood loss was related to sampling for blood gas analysis [<a href="#rid19">19</a>]. </p><p>These studies emphasize the need for NICU policies to ensure that only the minimal volume required for testing is drawn, and unnecessary tests are avoided.</p><p class="headingAnchor" id="H6"><span class="h2">Reduced red blood cell life span</span><span class="headingEndMark"> — </span>Red blood cell survival in newborn term infants is approximately 60 to 80 days, but decreases with decreasing gestational age to a range of 45 to 50 days in extremely low birth weight infants (ELBW) (BW below 1000 g) [<a href="#rid23">23</a>]. The reduced red cell life span contributes to the severity of anemia. Increased susceptibility to oxidant injury may contribute to shortened red cell survival in the neonate [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/d/html/7082.html" rel="external">"Red blood cell survival: Normal values and measurement"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Iron depletion</span><span class="headingEndMark"> — </span>Although it is not involved in its pathogenesis, iron depletion may impair recovery from AOP. Because of their rapid growth rate, preterm infants have increased utilization and depletion of iron stores and, as noted above, blood loss from phlebotomy. The administration of iron does not inhibit the fall in hemoglobin concentration due to AOP. However, in term infants, it reduces the incidence of iron deficiency anemia in the first year of life [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a>.)</p><p>Low levels of other nutrients, such as vitamin B12 or folate, do not appear to contribute to neonatal anemia [<a href="#rid1">1</a>]. However, limited clinical trial data suggest that in preterm neonates receiving erythropoietin therapy, supplementation with folate and B12 may enhance erythropoiesis [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H8"><span class="h1">PHYSIOLOGIC CONSEQUENCES</span><span class="headingEndMark"> — </span>The main physiologic consequence of anemia is impaired oxygen delivery. Oxygen delivery is the rate at which oxygen is transported from the lungs to the tissues. It depends upon the following (see  <a class="medical medical_review" href="/d/html/1623.html" rel="external">"Oxygen delivery and consumption"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac output</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen carrying capacity (affinity) of hemoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial oxygen saturation and oxygen tension</p><p></p><p>In preterm infants with anemia, compensatory physiologic changes that attempt to maintain adequate oxygen delivery include increases in heart rate and stroke volume, which improve cardiac output [<a href="#rid28">28</a>]. These are similar to compensatory changes that occur in older children and adults with anemia. </p><p>However, anemic preterm infants may be less able to maintain oxygen delivery because of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher levels of hemoglobin F (HbF)</strong> – HbF-containing red cells in the preterm infant have a considerably higher oxygen affinity than adult red blood cells, resulting in reduced release of oxygen to tissues (<a class="graphic graphic_figure graphicRef81216" href="/d/graphic/81216.html" rel="external">figure 2</a>). HbF binds poorly to 2,3 diphosphoglycerate (2,3-DPG), a potent modulator that diminishes the affinity of hemoglobin for oxygen. Decreased binding increases oxygen affinity and shifts the oxyhemoglobin dissociation curve to the left, resulting in decreased peripheral oxygen delivery (<a class="graphic graphic_figure graphicRef81216" href="/d/graphic/81216.html" rel="external">figure 2</a>). The proportion of HbF increases with decreasing gestational age, and is regulated developmentally so that HbF levels are similar at the same postmenstrual age [<a href="#rid29">29-31</a>]. The concentration of HbF in an infant born at 28 weeks gestation is approximately 90 percent, and decreases to approximately 60 percent at 10 weeks after birth, a value that is similar to that of an infant newly born at 38 weeks gestation [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concomitant respiratory disease</strong> – Many preterm neonates have hypoxia due to respiratory disorders, such as respiratory distress syndrome and bronchopulmonary dysplasia. (See  <a class="medical medical_review" href="/d/html/5055.html" rel="external">"Respiratory distress syndrome (RDS) in the newborn: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations on target oxygen saturation</strong> – For preterm infants requiring respiratory support, standard practice is to avoid hyperoxia due to its harmful effects (eg, risk of bronchopulmonary dysplasia and retinopathy of prematurity). (See  <a class="medical medical_review" href="/d/html/6263.html" rel="external">"Retinopathy of prematurity (ROP): Risk factors, classification, and screening", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Oxygen toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2626485609"><span class="h2">Timing of onset</span><span class="headingEndMark"> — </span>AOP typically occurs at 3 to 12 weeks after birth in infants &lt;32 weeks gestational age (GA). The onset of AOP occurs earlier in more premature infants [<a href="#rid1">1,32,33</a>]. The anemia typically resolves by three to six months of age.</p><p>In a study of 40 very low birth weight (VLBW) infants, average hemoglobin (Hgb) concentrations fell from 18.2 g/dL at birth to a mean nadir of 9.5 g/dL at six weeks of age [<a href="#rid34">34</a>]. Values of 7 to 8 g/dL were common even in the absence of significant phlebotomy losses. Hematocrit values were lowest in the smallest infant with average nadirs of 21 percent in infants with birth weights (BW) less than 1000 g, and 24 percent in infants with BW between 1000 and 1500 g.</p><p class="headingAnchor" id="H2572456080"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Many infants are asymptomatic despite having Hgb values &lt;7 g/dL [<a href="#rid35">35,36</a>]. However, other infants with AOP are symptomatic at similar or even higher Hgb levels because of a reduced capacity to compensate for the degree of anemia. (See <a class="local">'Physiologic consequences'</a> above.)</p><p>Symptoms associated with AOP may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia that is otherwise unexplained</p><p class="bulletIndent1"><span class="glyph">●</span>Poor weight gain</p><p class="bulletIndent1"><span class="glyph">●</span>Increased oxygen or respiratory support requirement</p><p class="bulletIndent1"><span class="glyph">●</span>Increased episodes of apnea or bradycardia</p><p></p><p>In a prospective study of preterm infants with BW &lt;1500 g, apneic episodes increased with decreasing hematocrit values and improved after red blood cell transfusion [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H1811291149"><span class="h2">Laboratory features</span><span class="headingEndMark"> — </span>The following laboratory findings are characteristic of AOP:</p><p class="bulletIndent1"><span class="glyph">●</span>Normocytic and normochromic anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low reticulocyte count.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While not routinely performed, bone marrow examination would show reduced red blood cell precursors [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While not routinely measured in clinical practice, serum erythropoietin levels are low in preterm infants during the first postnatal month compared with normal values in older children and adults (&lt;10 versus 15 mU/mL) and remain inappropriately low through the second postnatal month [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Clinicians who care for preterm infants should anticipate the development of AOP, particularly in very low birth weight (VLBW; &lt;1500 g) and extremely low birth weight (ELBW; &lt;1000 g) infants. Optimal nutrition (including iron supplementation) should be provided and patients should be monitored for signs of anemia. Blood sampling should be limited to essential testing, and microtechniques should be used to minimize blood loss due to phlebotomy [<a href="#rid22">22,38</a>]. (See <a class="local">'Blood loss from phlebotomy'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Routine iron supplementation</span><span class="headingEndMark"> — </span>The iron content at birth is lower in preterm infants than in term infants, and the iron stores of preterm infants often are depleted by two to three months of age. As a result, all preterm infants require iron supplementation. The target for daily intake is approximately 4 mg/kg per day.</p><p class="bulletIndent1"><span class="glyph">●</span>Breastfed infants – Breastfed infants should receive iron supplementation of 2 to 4 mg/kg per day through the first year of life. (See  <a class="medical medical_review" href="/d/html/5035.html" rel="external">"Breastfeeding the preterm infant", section on 'Vitamin D and iron supplements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formula-fed infants – Iron-fortified formulas have higher iron concentrations compared with breast milk and therefore formula-fed preterm infants require less additional iron supplementation compared with exclusively breastfed infants. The amount of supplemental iron required varies depending on the specific formula used, but it is typically 1 to 3 mg/kg per day. Low iron-containing preterm formulas should <strong>not</strong> be used as they do not adequately provide the necessary iron required for these patients. (See  <a class="medical medical_review" href="/d/html/5047.html" rel="external">"Nutritional composition of human milk and preterm formula for the premature infant"</a>.)</p><p></p><p>Although iron supplementation does not prevent AOP, iron supplementation allows for greater iron substrate when erythropoiesis is stimulated [<a href="#rid39">39</a>]. Iron supplementation does not necessarily prevent development of iron-deficiency anemia later in the first year of life. Thus, all preterm and term infants should undergo routine screening, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a>.)</p><p>Neonates who are treated with erythropoiesis stimulating agents (ESAs) require additional iron supplementation, as discussed below. (See <a class="local">'Additional iron supplementation'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Laboratory monitoring</span><span class="headingEndMark"> — </span>The hematocrit (HCT) or hemoglobin (Hgb) concentration should be monitored on a weekly basis in ELBW infants in the first weeks of life. Thereafter, it is generally not necessary to routinely monitor HCT/Hgb in healthy growing preterm infants. Infants with persistent illness (eg, bronchopulmonary dysplasia) or surgical issues may require ongoing monitoring.</p><p>Measuring the reticulocyte count is not routinely necessary but may occasionally be useful. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>If there is concern for another etiology of anemia besides AOP (eg, hemolytic anemia), measuring the reticulocyte count may be warranted. (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children", section on 'Reticulocyte count'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with borderline HCT/Hgb values (ie, values that are approaching thresholds for transfusion), the reticulocyte count can occasionally help guide decisions about RBC transfusion, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Transfusion thresholds'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In neonates who are receiving ESAs, reticulocyte indices (if available) can help guide the management of iron supplementation. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Transfusion</span><span class="headingEndMark"> — </span>RBC transfusion is the most rapidly effective treatment for AOP. However, transfusion is a temporary measure, it has well-established risks (eg, transfusion-transmitted infections, immune-mediated transfusion reactions, graft-versus-host disease, toxic effects of anticoagulants or preservatives), and has the disadvantage of further inhibiting erythropoiesis. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Risks'</a>.)</p><p>RBC transfusion is generally warranted when the degree of anemia causes symptoms or compromises oxygen delivery. Guidelines for RBC transfusion are based upon the degree of anemia (ie, the HCT/Hgb) and the patient's clinical status (ie, hemodynamic stability, respiratory support requirement, degree of symptoms). Signs and symptoms of anemia in preterm neonates may include otherwise unexplained tachycardia, poor weight gain, increased requirement of supplemental oxygen, and/or increased episodes of apnea or bradycardia. (See <a class="local">'Signs and symptoms'</a> above.)</p><p>For most preterm neonates with AOP, we recommend using a restrictive transfusion strategy (ie, transfusing at a lower Hgb level) rather than a liberal strategy (transfusing at a higher Hgb level). The thresholds we use to trigger transfusion are based chiefly upon HCT/Hgb levels, postnatal age, and clinical status (<a class="graphic graphic_table graphicRef140490" href="/d/graphic/140490.html" rel="external">table 2</a>). Additional details regarding RBC transfusion, including selection of RBC products and guidance on administration of transfusions are provided separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p>The practice of using a restrictive transfusion approach in preterm neonates is supported by randomized clinical trials and meta-analyses demonstrating that using restrictive transfusion thresholds reduces exposures to transfusion without increasing mortality or serious morbidity [<a href="#rid40">40-46</a>]. Most of these trials involved ELBW neonates. In a meta-analysis of five trials (3325 neonates), patients assigned to restrictive versus liberal transfusion protocols had similar mortality rates (14 percent in both groups; relative risk [RR] 0.99, 95% CI 0.84-1.17) [<a href="#rid40">40</a>]. Other neonatal morbidities (bronchopulmonary dysplasia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage) were also similar in both groups, as was hospital length of stay. In the two trials (1739 patients) that assessed neurodevelopmental outcomes at 18 to 24 months, rates of neurodevelopmental impairment were similar in both groups (39 versus 36 percent; RR 1.08, 95% CI 0.88-1.33) [<a href="#rid40">40,42,46</a>]. </p><p>Most of these trials demonstrated that restrictive transfusion protocols reduce the number of transfusions given. For example, in one of the largest trials (the ETTNO trial, which included 1013 ELBW neonates), the restrictive threshold group had a lower incidence of any transfusion (60 versus 79 percent) and lower cumulative volume of transfused blood (median 19 versus 40 mL) [<a href="#rid42">42</a>]. Similarly, in another large multicenter trial (the TOP trial, which included 1824 ELBW infants), patients in the restrictive threshold group on average received approximately two fewer transfusions compared with patients in the liberal threshold group (mean transfusions 4.4 versus 6.2) [<a href="#rid46">46</a>].</p><p>The transfusion thresholds used in the restrictive and liberal groups varied somewhat between the different trials. Most protocols were based upon postnatal age and respiratory support requirement. For example, in the ETTNO trial, the restrictive transfusion threshold for stable neonates ≤7 days old was HCT &lt;28 versus &lt;35 percent in the liberal transfusion protocol. For critically ill neonates ≤7 days old, transfusion thresholds were HCT &lt;34 and &lt;41 percent, respectively [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Erythropoiesis stimulating agents (ESAs)</span><span class="headingEndMark"> — </span>The pathogenetic importance of impaired erythropoietin production in AOP provides the rationale for the therapy with erythropoiesis stimulating agents (ESAs) including recombinant human erythropoietin (<a class="drug drug_pediatric" data-topicid="13273" href="/d/drug information/13273.html" rel="external">epoetin alfa</a>) and its longer-acting analog <a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">darbepoetin</a>. Use of ESAs varies by institution. </p><p></p><p class="headingAnchor" id="H2230252170"><span class="h3">Clinical use</span><span class="headingEndMark"> — </span>The practice of using ESAs is not standardized and varies from center to center. ESAs may be used in neonates in the following settings:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VLBW and ELBW infants whose parents/caregivers refuse blood transfusions for religious reasons. (see  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Erythropoiesis-stimulating agents (ESAs/EPO)'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with alloimmune hemolytic disease of the newborn. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management", section on 'Erythropoiesis stimulating agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with chronic kidney disease. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Erythropoiesis-stimulating agents'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For routine prophylaxis in at-risk preterm neonates. This includes all ELBW infants and select VLBW infants (ie, those requiring frequent blood draws or who are undergoing surgery). There is considerable practice variation regarding use of ESAs in this setting. At the author's institution, ESAs are not routinely used in this setting; however, other centers routinely use ESAs in all ELBW neonates. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Strategies to reduce RBC transfusion'</a>.) </p><p></p><p>For ELBW and VLBW infants, the optimal approach is uncertain. The arguments for and against routine use of ESAs in this setting are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The main argument <strong>against</strong> routine use is that when other strategies are used to reduce transfusion and donor exposure, the additional benefit of ESA therapy may be marginal. Other strategies include [<a href="#rid47">47,48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Providing optimal nutrition, including iron supplementation (see <a class="local">'Routine iron supplementation'</a> above and  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimizing blood loss from phlebotomy by using microtechniques and limiting blood sampling to essential testing (see <a class="local">'Blood loss from phlebotomy'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Using a restrictive approach to RBC transfusion (see <a class="local">'Transfusion'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Using satellite packs (RBC units from a single donor that are divided into multiple smaller aliquots, allowing for repeated transfusions from the same donor to the individual infant) (see  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Administration'</a>)</p><p></p><p class="bulletIndent1">In addition, the available clinical trial evidence suggest ESAs do not improve neurodevelopmental outcomes, as described below. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The main argument<strong> in favor </strong>of routine use of ESAs in this population is that they reduce transfusion rates and donor exposures. Limited data suggest they may be cost-saving [<a href="#rid49">49</a>]. Data supporting the efficacy of ESAs are summarized below. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p class="headingAnchor" id="H3410479647"><span class="h3">Dose</span><span class="headingEndMark"> — </span>When the decision is made to give an ESA, different agents and dosing regimens can be used (<a class="graphic graphic_table graphicRef140970" href="/d/graphic/140970.html" rel="external">table 3</a>) [<a href="#rid50">50-52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13206" href="/d/drug information/13206.html" rel="external">Darbepoetin alfa</a>: 10 mcg/kg per dose given subcutaneously or intravenous (IV) once weekly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous <a class="drug drug_pediatric" data-topicid="13273" href="/d/drug information/13273.html" rel="external">epoetin alfa</a>: 400 units/kg per dose given three times per week. For infants &lt;1000 g, this is given as 0.2 mL/kg of the 2000 units/mL solution. As the infant grows, preparations with higher concentrations (up to 10,000 units/mL) can be used. An alternative regimen is 1200 units/kg per dose given subcutaneously once weekly [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_pediatric" data-topicid="13273" href="/d/drug information/13273.html" rel="external">epoetin alfa</a>: 200 units/kg per dose as an infusion over at least four hours given three times a week. Alternatively, IV epoetin can be given as a daily dose of 200 units/kg per dose as a continuous infusion over 24 hours (typically as an addition to total parenteral nutrition [TPN]). IV epoetin should be mixed in a protein-containing solution (5 percent albumin or TPN) [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H870271745"><span class="h3">Additional iron supplementation</span><span class="headingEndMark"> — </span>Infants treated with ESAs require additional iron supplementation. Our suggested approach is as follows (<a class="graphic graphic_table graphicRef140970" href="/d/graphic/140970.html" rel="external">table 3</a>) [<a href="#rid52">52</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>For infants tolerating enteral feeds, iron is given enterally. A typical initial regimen consists of <a class="drug drug_pediatric" data-topicid="13056" href="/d/drug information/13056.html" rel="external">ferrous sulfate</a> 6 mg/kg of elemental iron once daily. Depending on the response, the dose can be increased if needed up to a maximum of 12 mg/kg per day (see <a class="local">'Monitoring'</a> below). When using doses ≥8 mg/kg, it should be divided into two daily doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants not yet tolerating enteral feeds (ie, those receiving TPN), supplementation can be given intravenously (IV) with either <a class="drug drug_pediatric" data-topicid="13058" href="/d/drug information/13058.html" rel="external">iron sucrose</a> or <a class="drug drug_pediatric" data-topicid="13057" href="/d/drug information/13057.html" rel="external">iron dextran</a> (for the latter, a test dose is recommended prior to starting maintenance dosing). Various dosing regimens have been described, including 1 mg/kg per day, 1.5 mg/kg twice weekly, or 3 to 6 mg/kg once weekly [<a href="#rid52">52,55-58</a>]. At some centers, IV iron is added to the TPN [<a href="#rid59">59</a>]. </p><p></p><p>Extremely low birth weight (ELBW) infants (birth weight &lt;1000 g) receiving ESA therapy are at risk for iron deficiency even if they are receiving iron supplementation [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H769581162"><span class="h3">Other supplements</span><span class="headingEndMark"> — </span>Other supplements that are typically given to neonates receiving ESA therapy include (<a class="graphic graphic_table graphicRef140970" href="/d/graphic/140970.html" rel="external">table 3</a>) [<a href="#rid52">52,53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multivitamin once daily</p><p class="bulletIndent1"><span class="glyph">●</span>Folate 50 micrograms orally once daily</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin E 15 international units orally once daily</p><p></p><p class="headingAnchor" id="H1887842792"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>The reticulocyte count, central hematocrit or hemoglobin concentration, absolute neutrophil count (ANC), and ferritin level are measured before and one to two weeks after starting ESA treatment. If the ANC falls below 1000/microL, the ESA should be held. </p><p>The neonate's response to therapy can be monitored with either of the following tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte hemoglobin content (ret-He; also called CHr) – If available at the center, the ret-He can be used to monitor adequacy of iron therapy during ESA treatment. Low ret-He values reflect early iron deficient erythropoiesis [<a href="#rid61">61-64</a>]. The ret-He is checked at two weeks of age and then every two to four weeks while on treatment. The goal is to maintain the ret-He in the range of 29 to 35 pg [<a href="#rid65">65</a>]. If the ret-He falls below 29 pg, iron supplementation should be increased. Many automated hematology instruments routinely report ret-He and other reticulocyte parameters. However, the ret-He may not be available in all laboratories. (See  <a class="medical medical_review" href="/d/html/4430.html" rel="external">"Automated complete blood count (CBC)", section on 'Reticulocytes'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum ferritin – Ferritin levels can also be used to assess adequacy of iron supplementation. If this strategy is used, ferritin levels should be monitored every two weeks. If the neonate's ferritin level is &lt;15 ng/mL, iron supplementation should be increased; if the level is &gt;400 ng/mL, iron therapy should be discontinued [<a href="#rid55">55</a>]. </p><p></p><p class="headingAnchor" id="H1488510170"><span class="h3">Discontinuing therapy</span><span class="headingEndMark"> — </span>We suggest discontinuing ESA therapy once the hematocrit is ≥50 percent or the neonate's corrected gestational age is ≥35 weeks, whichever is earlier. ESA therapy should be discontinued sooner if the neonate experiences adverse effects related to therapy (eg, neutropenia, hypertension, thrombosis). (See <a class="local">'Adverse effects'</a> below.)</p><p>ESA and iron therapy should generally not be held or discontinued following RBC transfusion except in the case of double exchange transfusion for alloimmune hemolytic anemia. (See  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management", section on 'Exchange transfusion'</a>.)</p><p class="headingAnchor" id="H2456206848"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Use of ESAs in preterm infants appears to be safe. In the available studies involving preterm neonates, the most common adverse effects were: </p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia, which is generally transient and resolves with stopping the agent [<a href="#rid66">66,67</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Iron deficiency, particularly if supplementation is inadequate [<a href="#rid67">67-69</a>].</p><p></p><p>Adverse effects that have been observed in other populations receiving ESAs (eg, patients with advanced kidney disease) include hypertension, seizures, rash, bone pain, and development of anti-erythropoietin antibodies. These have not been reported in preterm infants. Nevertheless, ESA therapy should be discontinued if the neonate experiences thrombotic complications, clinically significant hypertension, or seizures. (See  <a class="medical medical_review" href="/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis", section on 'Adverse effects of ESAs'</a> and  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors", section on 'Toxicity of colony-stimulating factors'</a>.)</p><p class="headingAnchor" id="H3655463189"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>ESAs lower transfusion requirements in ELBW and VLBW infants. However, among transfused patients, ESAs may not reduce the number of blood donors to which the infant is exposed, regardless of whether the ESA is administered early (within the first week of life) or late (at or after eight days of life). In addition, based on the available data, ESAs do not appear to improve neurodevelopmental outcomes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early (prophylactic) use</strong> – In a meta-analysis of 19 trials (1750 neonates), early ESA therapy (predominantly epoetin, started within the first eight days after birth) reduced the likelihood of needing a transfusion compared with no ESA therapy (52 versus 69 percent; relative risk [RR] 0.79, 95% CI 0.74-0.85) [<a href="#rid70">70</a>]. In the two trials (n = 165 neonates) that provided information on donor exposures among transfused neonates, there was little to no difference in the number of donor exposures between infants treated with ESAs compared with placebo (mean difference 0.05, 95% CI -0.33 to 0.42). Rates of necrotizing enterocolitis and intraventricular hemorrhage were lower in ESA-treated infants compared with control. Rates of retinopathy of prematurity were higher in ESA-treated infants compared with control, but the difference was not statistically significant. Mortality rates were similar in both groups. Many of the trials included in the meta-analysis had important methodologic limitations (lack of blinding, incomplete or selective reporting of outcomes). Thus, the certainty of these findings is low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late (therapeutic) use</strong> – In a meta-analysis of 21 trials (1202 neonates), late ESA therapy (predominantly epoetin, started 8 to 28 days after birth) reduced the likelihood of needing a transfusion compared with no ESA therapy (43 versus 60 percent; RR 0.72, 95% CI 0.65-0.79) [<a href="#rid71">71</a>]. However, the total volume of blood transfused was similar in both groups (mean difference 1.6 mL/kg less in the ESA group, 95% CI 5.8 mL/kg less to 2.6 mL/kg more; based upon five trials [197 neonates]). In the two trials (n = 190 neonates) that provided information on donor exposures among transfused neonates, the number of donor exposures in ESA-treated neonates was slightly higher compared with placebo (mean difference 0.45, 95% CI 0.20-0.69). Mortality rates were similar in both groups, as were rates of necrotizing enterocolitis, intraventricular hemorrhage, sepsis, and bronchopulmonary dysplasia. Rates of retinopathy of prematurity were higher in ESA-treated infants compared with control, but the finding did not achieve statistical significance (RR 1.27, 95% CI 0.99-1.64).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on neurodevelopment</strong> – In the previously described meta-analysis of trials evaluating early ESA therapy, rates of neurodevelopmental impairment (NDI) at 18 to 22 months corrected age were lower in ESA-treated infants compared with control (13 versus 21 percent; RR 0.62, 95% CI 0.48-0.80; based on four trials [1130 neonates]) [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">However, in two subsequent large multicenter trials that were not included in the meta-analysis, there was no apparent benefit of early ESA therapy on neurodevelopmental outcomes [<a href="#rid55">55,72,73</a>]. In the PENUT trial, which included 941 EPT infants who were randomized to epoetin or placebo starting within 24 hours after delivery, both groups had similar rates of moderate to severe NDI at age 22 to 26 months (38 percent in both arms; RR 0.97; 95% CI 0.79 to 1.18) [<a href="#rid55">55</a>]. In a separate report from the PENUT trial, both groups had similar brain magnetic resonance imaging (MRI) findings at term equivalent, which correlated with neurodevelopmental outcome as assessed by the Bayley Scales [<a href="#rid74">74</a>]. In the Swiss EPO trial, which included 448 preterm infants (GA between 26 weeks and 31 weeks and 6 days) randomized to epoetin or placebo starting at three hours after birth, both groups had similar mean scores on standardized developmental testing at age two years (mean Bayley MDI score 93.5 versus 94.5; difference -1.0, 95% CI -4.5 to 2.5]) [<a href="#rid72">72</a>]. Neurodevelopmental outcomes at five years of age were also similar [<a href="#rid73">73</a>]. </p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology, pathogenesis, and pathophysiology</strong> – Newborn infants have a fall in hematocrit soon after birth due primarily to impaired production of erythropoietin. Preterm infants have lower hemoglobin (Hgb) values at birth compared with term infants and the postnatal decline in Hgb occurs earlier and is more pronounced than the physiologic anemia seen in term infants. This is compounded by other factors that contribute to more severe anemia (blood loss from phlebotomy, reduced red blood cell [RBC] lifespan, depleted iron stores). Together, these processes are referred to as anemia of prematurity (AOP). (See <a class="local">'Causes and contributing factors'</a> above.)</p><p></p><p class="bulletIndent1">Preterm infants are at particular risk for impaired oxygen delivery in the setting of anemia because they often have concomitant respiratory disease and have high levels of hgb F, which is less efficient in releasing oxygen to tissues. (See <a class="local">'Physiologic consequences'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of onset</strong> – AOP typically occurs at 3 to 12 weeks after birth in infants and it typically resolves by three to six months of age. (See <a class="local">'Timing of onset'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Signs and symptoms</strong> – Many infants remain asymptomatic despite having Hgb levels &lt;7 g/dL. However, other infants may be symptomatic at similar or even higher hgb levels. Symptoms may include tachycardia, poor weight gain, increased requirement of supplemental oxygen, and/or increased frequency of apnea or bradycardia. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory features</strong> – The laboratory findings characteristic of AOP include normocytic and normochromic red blood cells, low reticulocyte count, and low erythropoietin levels. (See <a class="local">'Laboratory features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Key components of managing AOP include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Optimal nutrition, including iron supplementation. (See <a class="local">'Routine iron supplementation'</a> above and  <a class="medical medical_review" href="/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring for signs of anemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limiting blood loss from phlebotomy by performing only essential tests and using microtechniques. (See <a class="local">'Blood loss from phlebotomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Restrictive transfusion strategy – RBC transfusion is generally warranted when the degree of anemia causes symptoms or compromises oxygen delivery. For most preterm neonates with AOP, we recommend using a restrictive transfusion strategy (ie, transfusing at a lower Hgb level) rather than a liberal strategy (transfusing at a higher Hgb level) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The thresholds we use to trigger transfusion are based chiefly upon HCT/Hgb levels, postnatal age, and clinical status (<a class="graphic graphic_table graphicRef140490" href="/d/graphic/140490.html" rel="external">table 2</a>) (see <a class="local">'Transfusion'</a> above). Additional details regarding RBC transfusion in neonates are provided separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a> and  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Indications for transfusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of erythropoiesis stimulating agents (ESAs)</strong> – The practice of using ESAs is not standardized and varies from center to center (<a class="graphic graphic_table graphicRef140970" href="/d/graphic/140970.html" rel="external">table 3</a>). ESAs may be used in neonates in the following settings (see <a class="local">'Erythropoiesis stimulating agents (ESAs)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>VLBW and ELBW infants whose parents/caregivers refuse blood transfusions for religious reasons. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion", section on 'Erythropoiesis-stimulating agents (ESAs/EPO)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with alloimmune hemolytic disease of the newborn. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management", section on 'Erythropoiesis stimulating agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with chronic kidney disease. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Erythropoiesis-stimulating agents'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For routine prophylaxis in ELBW infants. There is considerable practice variation regarding use of ESAs in this setting and the optimal approach is uncertain. The advantages and disadvantages are discussed above. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="headingAnchor" id="H203863435"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Joyce M Koenig, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000; 27:681.</a></li><li><a class="nounderline abstract_t">Stockman JA 3rd, Graeber JE, Clark DA, et al. Anemia of prematurity: determinants of the erythropoietin response. J Pediatr 1984; 105:786.</a></li><li><a class="nounderline abstract_t">Brown MS, Phibbs RH, Garcia JF, Dallman PR. Postnatal changes in erythropoietin levels in untransfused premature infants. J Pediatr 1983; 103:612.</a></li><li><a class="nounderline abstract_t">Shannon KM, Naylor GS, Torkildson JC, et al. Circulating erythroid progenitors in the anemia of prematurity. N Engl J Med 1987; 317:728.</a></li><li><a class="nounderline abstract_t">Rhondeau SM, Christensen RD, Ross MP, et al. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the "anemia of prematurity". J Pediatr 1988; 112:935.</a></li><li><a class="nounderline abstract_t">Ohls RK, Liechty KW, Turner MC, et al. Erythroid "burst promoting" activity in serum of patients with the anemia of prematurity. J Pediatr 1990; 116:786.</a></li><li><a class="nounderline abstract_t">Malek A, Sager R, Eckardt KU, et al. Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system. Pflugers Arch 1994; 427:157.</a></li><li><a class="nounderline abstract_t">Schneider H, Malek A. Lack of permeability of the human placenta for erythropoietin. J Perinat Med 1995; 23:71.</a></li><li><a class="nounderline abstract_t">Widness JA, Schmidt RL, Sawyer ST. Erythropoietin transplacental passage--review of animal studies. J Perinat Med 1995; 23:61.</a></li><li><a class="nounderline abstract_t">Palis J, Segel GB. Developmental biology of erythropoiesis. Blood Rev 1998; 12:106.</a></li><li><a class="nounderline abstract_t">Brown MS, Garcia JF, Phibbs RH, Dallman PR. Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity. J Pediatr 1984; 105:793.</a></li><li><a class="nounderline abstract_t">Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997; 273:R1829.</a></li><li><a class="nounderline abstract_t">Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92:3218.</a></li><li><a class="nounderline abstract_t">Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992; 263:F474.</a></li><li><a class="nounderline abstract_t">Flake AW, Harrison MR, Adzick NS, Zanjani ED. Erythropoietin production by the fetal liver in an adult environment. Blood 1987; 70:542.</a></li><li><a class="nounderline abstract_t">Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15:551.</a></li><li><a class="nounderline abstract_t">Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.</a></li><li><a class="nounderline abstract_t">Rajakumar A, Conrad KP. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod 2000; 63:559.</a></li><li><a class="nounderline abstract_t">Hellström W, Forssell L, Morsing E, et al. Neonatal clinical blood sampling led to major blood loss and was associated with bronchopulmonary dysplasia. Acta Paediatr 2020; 109:679.</a></li><li><a class="nounderline abstract_t">Ringer SA, Richardson DK, Sacher RA, et al. Variations in transfusion practice in neonatal intensive care. Pediatrics 1998; 101:194.</a></li><li><a class="nounderline abstract_t">Puia-Dumitrescu M, Tanaka DT, Spears TG, et al. Patterns of phlebotomy blood loss and transfusions in extremely low birth weight infants. J Perinatol 2019; 39:1670.</a></li><li><a class="nounderline abstract_t">Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics 2000; 106:E19.</a></li><li><a class="nounderline abstract_t">KAPLAN E, HSU KS. Determination of erythrocyte survival in newborn infants by means of Cr51-labelled erythrocytes. Pediatrics 1961; 27:354.</a></li><li><a class="nounderline abstract_t">Shahal Y, Bauminger ER, Zmora E, et al. Oxidative stress in newborn erythrocytes. Pediatr Res 1991; 29:119.</a></li><li><a class="nounderline abstract_t">Robles R, Palomino N, Robles A. Oxidative stress in the neonate. Early Hum Dev 2001; 65 Suppl:S75.</a></li><li><a class="nounderline abstract_t">Haiden N, Schwindt J, Cardona F, et al. Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants. Pediatrics 2006; 118:2004.</a></li><li><a class="nounderline abstract_t">Haiden N, Klebermass K, Cardona F, et al. A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics 2006; 118:180.</a></li><li><a class="nounderline abstract_t">Bard H, Fouron JC, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. J Pediatr 1998; 132:630.</a></li><li><a class="nounderline abstract_t">Bard H. The postnatal decline of hemoglobin F synthesis in normal full-term infants. J Clin Invest 1975; 55:395.</a></li><li><a class="nounderline abstract_t">Bard H, Prosmanne J. Postnatal fetal and adult hemoglobin synthesis is preterm infants whose birth weight was less than 1,000 grams. J Clin Invest 1982; 70:50.</a></li><li><a class="nounderline abstract_t">Beuzard Y, Vainchenker W, Testa U, et al. Fetal to adult hemoglobin switch in cultures of early erythroid precursors from human fetuses and neonates. Am J Hematol 1979; 7:207.</a></li><li><a class="nounderline abstract_t">Stockman JA 3rd. Anemia of prematurity. Clin Perinatol 1977; 4:239.</a></li><li><a class="nounderline abstract_t">Stockman JA 3rd, Garcia JF, Oski FA. The anemia of prematurity. Factors governing the erythropoietin response. N Engl J Med 1977; 296:647.</a></li><li><a class="nounderline abstract_t">Stockman JA 3rd, Oski FA. RBC values in low-birth-weight infants during the first seven weeks of life. Am J Dis Child 1980; 134:945.</a></li><li><a class="nounderline abstract_t">Lachance C, Chessex P, Fouron JC, et al. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity. J Pediatr 1994; 125:278.</a></li><li><a class="nounderline abstract_t">Böhler T, Janecke A, Linderkamp O. Blood transfusion in late anemia of prematurity: effect on oxygen consumption, heart rate, and weight gain in otherwise healthy infants. Infusionsther Transfusionsmed 1994; 21:376.</a></li><li><a class="nounderline abstract_t">Zagol K, Lake DE, Vergales B, et al. Anemia, apnea of prematurity, and blood transfusions. J Pediatr 2012; 161:417.</a></li><li><a class="nounderline abstract_t">Madsen LP, Rasmussen MK, Bjerregaard LL, et al. Impact of blood sampling in very preterm infants. Scand J Clin Lab Invest 2000; 60:125.</a></li><li><a class="nounderline abstract_t">Berseth CL, Van Aerde JE, Gross S, et al. Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier. Pediatrics 2004; 114:e699.</a></li><li><a class="nounderline abstract_t">Wang P, Wang X, Deng H, et al. Restrictive versus liberal transfusion thresholds in very low birth weight infants: A systematic review with meta-analysis. PLoS One 2021; 16:e0256810.</a></li><li><a class="nounderline abstract_t">Ibrahim M, Ho SK, Yeo CL. Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants: a systematic review and meta-analysis. J Paediatr Child Health 2014; 50:122.</a></li><li><a class="nounderline abstract_t">Franz AR, Engel C, Bassler D, et al. Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial. JAMA 2020; 324:560.</a></li><li><a class="nounderline abstract_t">Whyte R, Kirpalani H. Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD000512.</a></li><li><a class="nounderline abstract_t">Whyte RK, Kirpalani H, Asztalos EV, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics 2009; 123:207.</a></li><li><a class="nounderline abstract_t">Venkatesh V, Khan R, Curley A, et al. The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. Br J Haematol 2012; 158:370.</a></li><li><a class="nounderline abstract_t">Kirpalani H, Bell EF, Hintz SR, et al. Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. N Engl J Med 2020; 383:2639.</a></li><li><a class="nounderline abstract_t">Birenbaum HJ, Pane MA, Helou SM, Starr KP. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants. South Med J 2006; 99:1059.</a></li><li><a class="nounderline abstract_t">New HV, Berryman J, Bolton-Maggs PH, et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol 2016; 175:784.</a></li><li><a class="nounderline abstract_t">Henry E, Christensen RD, Sheffield MJ, et al. Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates? J Perinatol 2015; 35:132.</a></li><li><a class="nounderline abstract_t">Calhoun DA, Christensen RD, Edstrom CS, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000; 27:733.</a></li><li><a class="nounderline abstract_t">Costa S, Romagnoli C, Zuppa AA, et al. How to administrate erythropoietin, intravenous or subcutaneous? Acta Paediatr 2013; 102:579.</a></li><li><a class="nounderline abstract_t">Ohls RK, Christensen RD, Kamath-Rayne BD, et al. A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants. Pediatrics 2013; 132:e119.</a></li><li><a class="nounderline abstract_t">Ohls RK, Roohi M, Peceny HM, et al. A randomized, masked study of weekly erythropoietin dosing in preterm infants. J Pediatr 2012; 160:790.</a></li><li><a class="nounderline abstract_t">Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 1996; 128:518.</a></li><li><a class="nounderline abstract_t">Juul SE, Comstock BA, Wadhawan R, et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med 2020; 382:233.</a></li><li><a class="nounderline abstract_t">Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997; 131:661.</a></li><li><a class="nounderline abstract_t">Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics 2001; 107:78.</a></li><li><a class="nounderline abstract_t">Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996; 129:258.</a></li><li><a class="nounderline abstract_t">Domellöf M, Szitanyi P, Simchowitz V, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Iron and trace minerals. Clin Nutr 2018; 37:2354.</a></li><li><a class="nounderline abstract_t">Siddappa AM, Olson RM, Spector M, et al. High Prevalence of Iron Deficiency Despite Standardized High-Dose Iron Supplementation During Recombinant Erythropoietin Therapy in Extremely Low Gestational Age Newborns. J Pediatr 2020; 222:98.</a></li><li><a class="nounderline abstract_t">German K, Vu PT, Irvine JD, Juul SE. Trends in reticulocyte hemoglobin equivalent values in critically ill neonates, stratified by gestational age. J Perinatol 2019; 39:1268.</a></li><li><a class="nounderline abstract_t">Amin K, Bansal M, Varley N, et al. Reticulocyte hemoglobin content as a function of iron stores at 35-36 weeks post menstrual age in very premature infants. J Matern Fetal Neonatal Med 2021; 34:3214.</a></li><li><a class="nounderline abstract_t">Löfving A, Domellöf M, Hellström-Westas L, Andersson O. Reference intervals for reticulocyte hemoglobin content in healthy infants. Pediatr Res 2018; 84:657.</a></li><li><a class="nounderline abstract_t">Nii M, Okamoto T, Sugiyama T, et al. Reticulocyte hemoglobin content changes after treatment of anemia of prematurity. Pediatr Int 2022; 64:e15330.</a></li><li><a class="nounderline abstract_t">Bahr TM, Carr NR, Christensen TR, et al. Early iron supplementation and iron sufficiency at one month of age in NICU patients at-risk for iron deficiency. Blood Cells Mol Dis 2021; 90:102575.</a></li><li><a class="nounderline abstract_t">Ohls RK, Christensen RD. Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity. J Pediatr 1991; 119:781.</a></li><li><a class="nounderline abstract_t">Halpérin DS. Use of recombinant erythropoietin in treatment of the anemia of prematurity. Am J Pediatr Hematol Oncol 1991; 13:351.</a></li><li><a class="nounderline abstract_t">Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 79:F44.</a></li><li><a class="nounderline abstract_t">Bechensteen AG, Hågå P, Halvorsen S, et al. Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake. Eur J Pediatr 1997; 156:56.</a></li><li><a class="nounderline abstract_t">Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev 2020; 2:CD004863.</a></li><li><a class="nounderline abstract_t">Aher SM, Ohlsson A. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev 2020; 1:CD004868.</a></li><li><a class="nounderline abstract_t">Natalucci G, Latal B, Koller B, et al. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. JAMA 2016; 315:2079.</a></li><li><a class="nounderline abstract_t">Natalucci G, Latal B, Koller B, et al. Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants. JAMA 2020; 324:2324.</a></li><li><a class="nounderline abstract_t">Mayock DE, Gogcu S, Puia-Dumitrescu M, et al. Association between Term Equivalent Brain Magnetic Resonance Imaging and 2-Year Outcomes in Extremely Preterm Infants: A Report from the Preterm Erythropoietin Neuroprotection Trial Cohort. J Pediatr 2021; 239:117.</a></li></ol></div><div id="topicVersionRevision">Topic 4962 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The use of erythropoietin in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6502312" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anemia of prematurity: determinants of the erythropoietin response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6194281" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Postnatal changes in erythropoietin levels in untransfused premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627181" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Circulating erythroid progenitors in the anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3373403" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the "anemia of prematurity".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184214" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Erythroid "burst promoting" activity in serum of patients with the anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058465" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658324" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lack of permeability of the human placenta for erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Erythropoietin transplacental passage--review of animal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661799" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Developmental biology of erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6502313" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435635" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Developmental regulation of erythropoietin and erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787158" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Erythropoietin mRNA expression in human fetal and neonatal tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415576" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3300814" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Erythropoietin production by the fetal liver in an adult environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10611972" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539918" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906065" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505053" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neonatal clinical blood sampling led to major blood loss and was associated with bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445491" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Variations in transfusion practice in neonatal intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31582812" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Patterns of phlebotomy blood loss and transfusions in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phlebotomy overdraw in the neonatal intensive care nursery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13751271" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determination of erythrocyte survival in newborn infants by means of Cr51-labelled erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2014146" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Oxidative stress in newborn erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755038" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oxidative stress in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079573" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818564" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580761" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1127106" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The postnatal decline of hemoglobin F synthesis in normal full-term infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6177718" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Postnatal fetal and adult hemoglobin synthesis is preterm infants whose birth weight was less than 1,000 grams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/94975" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fetal to adult hemoglobin switch in cultures of early erythroid precursors from human fetuses and neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/332429" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/851485" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The anemia of prematurity. Factors governing the erythropoietin response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424854" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : RBC values in low-birth-weight infants during the first seven weeks of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040778" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873916" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Blood transfusion in late anemia of prematurity: effect on oxygen consumption, heart rate, and weight gain in otherwise healthy infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22494873" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anemia, apnea of prematurity, and blood transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817399" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of blood sampling in very preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545616" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34460843" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Restrictive versus liberal transfusion thresholds in very low birth weight infants: A systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118127" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32780138" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071798" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117884" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22639894" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33382931" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100024" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861734" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guidelines on transfusion for fetuses, neonates and older children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25254330" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986638" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Consistent approaches to procedures and practices in neonatal hematology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414120" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : How to administrate erythropoietin, intravenous or subcutaneous?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776118" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137666" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A randomized, masked study of weekly erythropoietin dosing in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618186" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31940698" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403642" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134438" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765624" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30078716" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Iron and trace minerals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32418819" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High Prevalence of Iron Deficiency Despite Standardized High-Dose Iron Supplementation During Recombinant Erythropoietin Therapy in Extremely Low Gestational Age Newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350450" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trends in reticulocyte hemoglobin equivalent values in critically ill neonates, stratified by gestational age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662016" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reticulocyte hemoglobin content as a function of iron stores at 35-36 weeks post menstrual age in very premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30140071" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reference intervals for reticulocyte hemoglobin content in healthy infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36321339" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Reticulocyte hemoglobin content changes after treatment of anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33989937" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Early iron supplementation and iron sufficiency at one month of age in NICU patients at-risk for iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1941387" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1793163" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Use of recombinant erythropoietin in treatment of the anemia of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797624" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007493" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32048730" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Early erythropoiesis-stimulating agents in preterm or low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990982" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27187300" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289818" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454953" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Association between Term Equivalent Brain Magnetic Resonance Imaging and 2-Year Outcomes in Extremely Preterm Infants: A Report from the Preterm Erythropoietin Neuroprotection Trial Cohort.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
